病例报告：米替福新长期治疗感染墨氏无鞭毛体的弥漫性皮肤利什曼病患者取得短暂成功。
Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.
机构信息
Department of Medicine, University Hospital Dr. José Eleuterio González, Monterrey, Nuevo Leon, México.
出版信息
Am J Trop Med Hyg. 2013 Jan;88(1):153-6. doi: 10.4269/ajtmh.2012.11-0592. Epub 2012 Dec 12.
Abstract
Leishmania sp. is an intracellular parasite that causes a variable degree of clinical manifestations, especially in the skin. We present the case of a 38-year-old male with a chronic history of mucocutaneous disease present since childhood that generated deformity, loss of cartilage in the ears and nose, and scarring that limited his range of motion. The parasite was identified as L. mexicana mexicana. The patient was treated with a 3-month course of oral miltefosine with overwhelming results.
摘要
利什曼原虫是一种细胞内寄生虫，可引起不同程度的临床表现，尤其是在皮肤中。我们报告了一例 38 岁男性病例，他自幼患有慢性黏膜皮肤疾病，导致耳和鼻部畸形、软骨缺失以及疤痕形成，从而限制了其运动范围。该寄生虫被鉴定为墨西哥利什曼原虫。该患者接受了 3 个月的米替福新口服治疗，效果显著。
相似文献
1
Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.病例报告：米替福新长期治疗感染墨氏无鞭毛体的弥漫性皮肤利什曼病患者取得短暂成功。
Am J Trop Med Hyg. 2013 Jan;88(1):153-6. doi: 10.4269/ajtmh.2012.11-0592. Epub 2012 Dec 12.
2
Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.米替福新治疗后由墨西哥利什曼原虫（利什曼原虫属）引起的新世界弥漫性皮肤利什曼病复发。
Am J Trop Med Hyg. 2006 Dec;75(6):1074-7.
3
In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.来自一名弥漫性皮肤利什曼病患者的亚马逊利什曼原虫分离株的体外和体内米替福新敏感性
PLoS Negl Trop Dis. 2014 Jul 17;8(7):e2999. doi: 10.1371/journal.pntd.0002999. eCollection 2014 Jul.
4
[Miltefosine for disseminated cutaneous leishmaniasis].[米替福新治疗播散性皮肤利什曼病]
Biomedica. 2006 Oct;26 Suppl 1:13-6.
5
Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.米替福新成功治疗一名感染HIV-1的严重免疫功能低下患者的播散性皮肤利什曼病。
Clin Infect Dis. 2005 Jun 15;40(12):e120-4. doi: 10.1086/430444. Epub 2005 Apr 27.
6
New World and Old World Leishmania Infections: A Practical Review.新旧世界利什曼原虫感染：实用综述
Dermatol Clin. 2015 Jul;33(3):579-93. doi: 10.1016/j.det.2015.03.018.
7
Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate.巴西利什曼原虫两性霉素 B 耐药性：巴西临床分离株的体外和体内特征。
PLoS Negl Trop Dis. 2024 May 20;18(5):e0012175. doi: 10.1371/journal.pntd.0012175. eCollection 2024 May.
8
Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.弥漫性皮肤利什曼病对米替福新有反应，但随后会复发。
Br J Dermatol. 2007 Jun;156(6):1328-35. doi: 10.1111/j.1365-2133.2007.07872.x. Epub 2007 Apr 17.
9
Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.口服米替福新治疗黑热病后皮肤利什曼病——三例经验
Int J Dermatol. 2010 May;49(5):565-9. doi: 10.1111/j.1365-4632.2010.04326.x.
10
Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.用十六烷基磷胆碱（Miltex）进行局部治疗可有效减轻实验性皮肤利什曼病的寄生虫负荷。
Trans R Soc Trop Med Hyg. 1999 Jan-Feb;93(1):85-90. doi: 10.1016/s0035-9203(99)90192-x.
引用本文的文献
1
Successful Treatment of Rapidly Evolving Cutaneous Leishmaniasis With Amphotericin B and Miltefosine in an Immigrant From Venezuela.用两性霉素B和米替福新成功治疗一名来自委内瑞拉移民的快速进展性皮肤利什曼病
Open Forum Infect Dis. 2023 Dec 28;11(2):ofad683. doi: 10.1093/ofid/ofad683. eCollection 2024 Feb.
2
Successful treatment of diffuse cutaneous leishmaniasis caused by Leishmania amazonensis.成功治疗由亚马逊利什曼原虫引起的皮肤弥漫性利什曼病。
An Bras Dermatol. 2021 Sep-Oct;96(5):602-604. doi: 10.1016/j.abd.2021.03.003. Epub 2021 Jul 15.
3
Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.米替福新治疗皮肤利什曼病的试点研究：来自埃塞俄比亚的报告。
PLoS Negl Trop Dis. 2021 May 28;15(5):e0009460. doi: 10.1371/journal.pntd.0009460. eCollection 2021 May.
4
Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.米替福新治疗皮肤利什曼病：10 例儿科患者的病例系列。
Acta Derm Venereol. 2020 Oct 19;100(18):adv00322. doi: 10.2340/00015555-3669.
5
An update on pharmacotherapy for leishmaniasis.利什曼病药物治疗的最新进展。
Expert Opin Pharmacother. 2015 Feb;16(2):237-52. doi: 10.1517/14656566.2015.973850. Epub 2014 Oct 25.
本文引用的文献
1
Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review.过去十年新世界皮肤利什曼病治疗进展：系统文献综述
An Bras Dermatol. 2011 May-Jun;86(3):497-506. doi: 10.1590/s0365-05962011000300012.
2
3
Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.联合使用酮康唑、米替福新与免疫调节剂——苦豆碱治疗内脏利什曼病（黑热病）的疗效改善。
Acta Trop. 2011 Aug;119(2-3):188-93. doi: 10.1016/j.actatropica.2011.05.017. Epub 2011 Jun 7.
4
CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists.弥漫性皮肤利什曼病患者的 CD8 细胞表现出功能衰竭：后者可被 TLR2 激动剂体外逆转。
PLoS Negl Trop Dis. 2010 Nov 2;4(11):e871. doi: 10.1371/journal.pntd.0000871.
5
Eight cases of feline cutaneous leishmaniasis in Texas.德克萨斯州的 8 例猫皮肤利什曼病。
Vet Pathol. 2010 Nov;47(6):1076-81. doi: 10.1177/0300985810382094. Epub 2010 Sep 8.
6
Current diagnosis and treatment of visceral leishmaniasis.内脏利什曼病的当前诊断和治疗。
Expert Rev Anti Infect Ther. 2010 Aug;8(8):919-44. doi: 10.1586/eri.10.78.
7
Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.免疫疗法作为治疗利什曼病的策略：文献综述。
Immunotherapy. 2009 Sep;1(5):765-76. doi: 10.2217/imt.09.40.
8
New antileishmanial candidates and lead compounds.新型抗利什曼原虫候选药物和先导化合物。
Curr Opin Chem Biol. 2010 Aug;14(4):447-55. doi: 10.1016/j.cbpa.2010.03.023. Epub 2010 Apr 17.
9
Combination therapy for visceral leishmaniasis.内脏利什曼病的联合治疗。
Lancet Infect Dis. 2010 Mar;10(3):184-94. doi: 10.1016/S1473-3099(10)70011-6.
10
Cutaneous leishmaniasis in Texas.德克萨斯州的皮肤利什曼病。
J Am Acad Dermatol. 2010 Mar;62(3):508-10. doi: 10.1016/j.jaad.2009.08.034.
Zotero 插件